Results 51 to 60 of about 1,702,455 (203)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Purpurin Alleviates Chemotherapy‐Induced Thrombocytopenia Through Estrogen Receptor α Dependent Phosphoinositide 3‐Kinase/Protein Kinase B Signalling

Phytotherapy Research, EarlyView.
Schematic overview of the in vitro and in vivo evaluation of purpurin in promoting MK maturation and platelet production, through ESR1/PI3K/AKT. ABSTRACT Chemotherapy‐induced thrombocytopenia (CIT) increases bleeding risk and compromises chemotherapy delivery.
Xiaolin Gan, Xinle Wang, Lu Hao, Xiaoqin Tang, Zhixuan Liu, Long Wang, Xiang Xie, Xiang Li, Chunling Zhao, Yan Li, Xinwu Huang, Yuanzhi Liu, Jianming Wu   +12 more
wiley   +1 more source

Soluble Thrombopoietin Receptor Fragments and Uses Thereof

, 2023
The present invention relates to a polypeptide comprising the extracellular domain of the thrombopoietin receptor or fragments thereof, and its use as a medicament.
Université Catholique de Louvain, Constantinescu, Stefan N., Nedelec, Audrey, Papadopoulos, Nicolas   +3 more
core  

Agonist-Specific Conformations of the M₂ Muscarinic Acetylcholine Receptor Assessed by Molecular Dynamics

, 2020
Binding of muscarinic ligands, both antagonists and agonists, and their effects on the conformation of the M2 acetylcholine receptor were modeled in silico and compared to experimental data.
Alena Randáková, John Boulos (8575554), John Boulos, Vladimír Doležal (8575548), Jan Jakubík (8575557), Alena Randáková (8575542), Dominik Nelic (8575545), Esam E. El-Fakahany, Jan Jakubík, Vladimír Doležal, Esam E. El-Fakahany (8575551), Dominik Nelic   +11 more
core   +2 more sources

Eltrombopag in Good’s Syndrome

Case Reports in Hematology, 2014
Good’s syndrome is a rare acquired immunodeficiency associated with thymoma. Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias.
Håvard Anton Kristiansen, Signe Spetalen, Yngvar Fløisand, Dag Heldal   +3 more
doaj   +1 more source

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial

eJHaem, 2023
Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux   +10 more
doaj   +1 more source

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease

Journal of Blood Medicine, 2019
Abraham Z Cheloff, Hanny Al-Samkari Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USACorrespondence: Hanny Al-SamkariDivision of Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson ...
Cheloff AZ, Al-Samkari H
doaj  

Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report

Public Health Challenges, Volume 5, Issue 4, December 2026.
ABSTRACT Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue,
Riazullah, Hakim Ullah Wazir, Aafeen Mujeeb, Hamid Ahmad, Hameed Ur Rehman, Inibehe Ime Okon   +5 more
wiley   +1 more source

Real-world experience with romiplostim in the management of primary immune thrombocytopenia in Iraqi adult patients

Iraqi Journal of Hematology
BACKGROUND: Low platelet counts resulting from increased platelet breakdown and poor platelet generation are the hallmarks of immune thrombocytopenia (ITP), an autoimmune illness.
Alaadin Sahham Naji, Alhan A. Alkhalidi, Luma Essa Hammodi, Ahmed Mjali   +3 more
doaj   +1 more source

Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis

Haematologica, 2018
Corticosteroids such as prednisolone and dexamethasone have been established as up-front therapy for the treatment of newly diagnosed immune thrombocytopenia.
Yasuyuki Arai, Tomoyasu Jo, Hiroyuki Matsui, Tadakazu Kondo, Akifumi Takaori-Kondo   +4 more
doaj   +1 more source